Mechanisms of immune escape after allogeneic hematopoietic cell transplantation

被引:114
|
作者
Zeiser, Robert [1 ]
Vago, Luca [2 ,3 ]
机构
[1] Freiburg Univ, Med Ctr, Fac Med, Dept Hematol Oncol & Stem Cell Transplantat, Freiburg, Germany
[2] Ist Sci San Raffaele, Unit Immunogenet Leukemia Genom & Immunobiol, Via Olgettina 60, Milan, Italy
[3] Ist Sci San Raffaele, Hematol & Bone Marrow Transplantat Unit, Via Olgettina 60, Milan, Italy
基金
欧洲研究理事会;
关键词
ACUTE MYELOID-LEUKEMIA; DONOR LYMPHOCYTE INFUSION; BONE-MARROW-TRANSPLANTATION; CLASS-II TRANSACTIVATOR; MHC GENE-EXPRESSION; T-CELL; MYELODYSPLASTIC SYNDROME; SALVAGE THERAPY; TREAT RELAPSE; TGF-BETA;
D O I
10.1182/blood-2018-10-846824
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Relapse of the original disease is a major cause of death after allogeneic hematopoietic cell transplantation for acute leukemias. There is growing evidence that relapses may be explained not only by resistance to chemotherapy but also by the escape of tumor cells from the control of the allogeneic immune response. Mechanisms of immune evasion can involve abrogation of leukemia cell recognition due to loss of HLA genes, immunosuppression by immune-checkpoint ligand expression, production of anti-inflammatory factors, release of metabolically active enzymes, loss of proinflammatory cytokine production, and acquisition of novel driver mutations that promote leukemia outgrowth. These mechanisms, and therapeutic targeting of immune escape, will be discussed. We divide the evidence in support of immune-escape mechanisms into animal studies, human laboratory studies, and human clinical experience. A better understanding of the molecular pathways connected to immune escape and relapse may help to improve our therapeutic armamentarium against acute myeloid leukemia relapse.
引用
收藏
页码:1290 / 1297
页数:8
相关论文
共 50 条
  • [21] Indications for Allogeneic Hematopoietic Cell Transplantation in Myelodysplastic Syndrome
    Danielson, Nathalie
    Byrne, Michael
    CURRENT HEMATOLOGIC MALIGNANCY REPORTS, 2020, 15 (04) : 268 - 275
  • [22] Allogeneic hematopoietic stem cell transplantation for myelodysplastic syndromes
    Gournay, Viviane
    Robin, Marie
    BULLETIN DU CANCER, 2023, 110 (11) : 1168 - 1175
  • [23] Current Status of Allogeneic Hematopoietic Cell Transplantation for MDS
    Xu, Feng
    Deeg, Joachim
    CURRENT PHARMACEUTICAL DESIGN, 2012, 18 (22) : 3215 - 3221
  • [24] Thymus and immune reconstitution after allogeneic hematopoietic stem cell transplantation in humans: never say never again
    Toubert, A.
    Glauzy, S.
    Douay, C.
    Clave, E.
    TISSUE ANTIGENS, 2012, 79 (02): : 83 - 89
  • [25] Solid cancers after allogeneic hematopoietic cell transplantation
    Rizzo, J. Douglas
    Curtis, Rochelle E.
    Socie, Gerard
    Sobocinski, Kathleen A.
    Gilbert, Ethel
    Landgren, Ola
    Travis, Lois B.
    Travis, William D.
    Flowers, Mary E. D.
    Friedman, Debra L.
    Horowitz, Mary M.
    Wingard, John R.
    Deeg, H. Joachim
    BLOOD, 2009, 113 (05) : 1175 - 1183
  • [26] Quality of life after allogeneic hematopoietic cell transplantation
    Pidala, Joseph
    Anasetti, Claudio
    Jim, Heather
    BLOOD, 2009, 114 (01) : 7 - 19
  • [27] T Cell Immunotherapy for Immune Reconstitution and GVHD Prevention After Allogeneic Hematopoietic Stem Cell Transplantation
    Lucarelli B.
    Merli P.
    Strocchio L.
    Cefalo M.G.
    Brescia L.P.
    Locatelli F.
    Current Stem Cell Reports, 2015, 1 (4) : 206 - 214
  • [28] Immune reconstitution after hematopoietic cell transplantation
    Bosch, Mark
    Khan, Faisal M.
    Storek, Jan
    CURRENT OPINION IN HEMATOLOGY, 2012, 19 (04) : 324 - 335
  • [29] Immune Reconstitution after Allogeneic Hematopoietic Stem Cell Transplantation: Time To T Up the Thymus
    Chaudhry, Mohammed S.
    Velardi, Enrico
    Malard, Florent
    van den Brink, Marcel R. M.
    JOURNAL OF IMMUNOLOGY, 2017, 198 (01) : 40 - 46
  • [30] Quality of life and outcomes in patients ≥ 60 years of age after allogeneic hematopoietic cell transplantation
    Hamilton, B. K.
    Rybicki, L.
    Dabney, J.
    McLellan, L.
    Haddad, H.
    Foster, L.
    Abounader, D.
    Kalaycio, M.
    Sobecks, R.
    Dean, R.
    Duong, H.
    Hill, B. T.
    Bolwell, B. J.
    Copelan, E. A.
    BONE MARROW TRANSPLANTATION, 2014, 49 (11) : 1426 - 1431